Publications by Etienne Meylan

Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth

Freddy Radtke, Nadine Fournier, Amber Dawn Bowler, Etienne Meylan, Anita Bodac, Justine Pascual, Vincent Roh

Elevated peripheral blood and tumor-infiltrating neutrophils are often associated with a poor patient prognosis. However, therapeutic strategies to target these cells are difficult to implement due to the life-threatening risk of neutropenia. In a genetica ...

Springernature2024

Hyperthermic Intrathoracic Chemotherapy (HITOC) Improves Malignant Pleural Mesothelioma Control Through a Tumor Specific Cytotoxic Immune Response

Paul Joseph Dyson, Aspasia Gkasti, Etienne Meylan, Yan Hao

Oxford Univ Press2023

Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma

Daniel Constam, Etienne Meylan, Julien Robert Rémi Faget, Olivier Andreas Dubey, Katarina Pinjusic

Background Activin-A, a transforming growth factor beta family member, is secreted by many cancer types and is often associated with poor disease prognosis. Previous studies have shown that Activin-A expression can promote cancer progression and reduce the ...

BMJ PUBLISHING GROUP2022

Anti-Ly6G binding and trafficking mediate positive neutrophil selection to unleash the anti-tumor efficacy of radiation therapy

Etienne Meylan, Gael Luis Boivin, Caroline Anne-Lyse Contat, Pierre-Benoit Bernard Ancey

The anti-Ly6G antibody is used to deplete Ly6G(pos) neutrophils and study their role in diverse pathologies. However, depletion is never absolute, as Ly6G(low) neutrophils resistant to depletion rapidly emerge. Studying the functionality of these residual ...

2021

GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy

Nadine Fournier, Etienne Meylan, Gael Luis Boivin, Caroline Anne-Lyse Contat, Justine Pascual, Pierre-Benoit Bernard Ancey, Silvia Sabatino

Neutrophils are the most abundant circulating leucocytes and are essential for innate immunity. In cancer, pro- or antitumor properties have been attributed to tumor-associated neutrophils (TAN). Here, focusing on TAN accumulation within lung tumors, we id ...

AMER ASSOC CANCER RESEARCH2021

Determinants of tumor resistance to anti-angiogenic immunotherapy in mouse models of Kras-mutant NSCLC

Michele De Palma, Bruno Torchia, Etienne Meylan, Chiara Cianciaruso, Sina Nassiri, Ioanna Keklikoglou, Ece Kadioglu, Amaia Martinez Usatorre, Alan Nicolas Thierry Guichard

AMER ASSOC CANCER RESEARCH2021

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Michele De Palma, Nadine Fournier, Bruno Torchia, Etienne Meylan, Chiara Cianciaruso, Sina Nassiri, Ioanna Keklikoglou, Ece Kadioglu, Gael Luis Boivin, Amaia Martinez Usatorre

Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of nonsmall cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic d ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Neutrophils in the era of immune checkpoint blockade

Etienne Meylan, Julien Robert Rémi Faget

The immune checkpoint blockade-based immunotherapies are revolutionizing cancer management. Tumor-associated neutrophils (TANs) were recently highlighted to have a pivotal role in modulating the tumor microenvironment and the antitumor immune response. How ...

BMJ PUBLISHING GROUP2021

Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma

Paul Joseph Dyson, Etienne Meylan, Julien Robert Rémi Faget, Aspasia Gkasti, Yameng Hao, Maxime Reichenbach

OBJECTIVES: Malignant pleural mesothelioma (MPM) is a deadly disease with limited treatment options. Approaches to enhance patient immunity against MPM have been tested but shown variable results. Previously, we have demonstrated interesting vascular modul ...

OXFORD UNIV PRESS INC2020

Mechanisms Of Lung Cancer Hyper-Progression Promoted By Pd-1 Immune Checkpoint Blockade

Etienne Meylan, Julien Robert Rémi Faget, Amaia Martinez Usatorre

BMJ PUBLISHING GROUP2020